Understand how the immune system recognizes cancer
Explain recognition, activation and access before comparing checkpoint drugs, vaccines or engineered cells.
This is a foundation path for readers new to immunology. Treatment names become easier to understand once we separate what a cell can recognize from whether it is able to act.
The big ideas
- Innate immunity uses broad sensing systems; adaptive immunity uses diverse antigen-specific receptors and can form memory.
- Antigen display, receptor recognition and immune-cell activation are separate steps.
- More immune cells in a sample do not guarantee tumor-specific killing.
- Therapy formats solve different problems and can share different failure points.
The map
Effective killing needs the whole chain, rather than one positive marker.
Meet the cells
Begin with innate and adaptive immunity and the immune-cell roster. Then distinguish cross-presentation, T-cell priming and cell states. These explanations supply the vocabulary for the lessons rather than treating every immune cell as a cancer-killing cell.
A T-cell receptor (TCR) reads a peptide–display complex; a chimeric antigen receptor (CAR) usually reads an accessible surface target.
Follow these lessons
Suggested reading budgets, not measured completion times:
| Step | Lesson | Question | Minutes |
|---|---|---|---|
| 1 | Dendritic cells | How does a T cell encounter a tumor-derived antigen? | 8 |
| 2 | HLA | What is displayed, and on which molecule? | 5 |
| 3 | TCRs and sequencing | What does receptor identity establish? | 10 |
| 4 | T-cell states | What changes a cell’s ability to act? | 8 |
| 5 | Hot, excluded and cold patterns | Where are the immune cells? | 8 |
| 6 | Escape mechanisms | Which step can the tumor disrupt? | 8 |
| 7 | CAR, TCR and TIL comparison | Which recognition system does a cell therapy use? | 8 |
Where treatments intervene
Checkpoint drugs block inhibitory pathways in existing immune responses. Vaccines aim to prime or expand antigen-reactive responses. Engineered TCR (T-cell receptor)-T gives cells a receptor for a peptide–HLA (human leukocyte antigen) complex. Surface-antigen CAR (chimeric antigen receptor)-T uses an engineered receptor for an accessible surface target. Antibody-based engagers can link a target to immune-cell activation; TCR-based engagers still require a peptide–HLA complex.
Antibodies have binding regions called Fab and a constant region called Fc. Fc can recruit immune functions depending on format. Blocking a signal, recruiting an effector and delivering an attached payload are different uses of antibody binding. An anti-PD-1 antibody is not simply a tumor-targeted cell-killing antibody.
Try it
A clone expands in blood after a vaccine. What would strengthen the claim that it can kill tumor?
Answer: Evidence for specificity to the intended peptide–HLA complex, tumor-cell recognition, appropriate function and access. Expansion alone is a candidate signal.
Explain it back: “Recognition selects a target; activation and access determine whether a response can happen.”
Applied to Diana
Use the immune-context question and the checkpoint safety decision for current interpretation. A favorable mechanism does not authorize a treatment combination.
Takeaway: Ask what is recognized, how the cell is activated and whether it reaches the tumor.
Vocabulary: TIL means tumor-infiltrating lymphocyte.
What remains uncertain
A measured cell pattern or response does not identify every bottleneck. Mechanism evidence and treatment effects vary by cancer, product and setting. No single marker establishes useful recognition or clinical benefit.
Sources and scope
Source check: October 8, 2026; expert and learner review pending. Detailed lessons carry their mechanism sources.